Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers (Q34353892)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers	scientific article

Statements

scholarly article

1 reference

1 August 2017

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers (English)

1 reference

1 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

8

object named as

Joo-Youn Cho

1 reference

1 August 2017

author name string

Namyi Gu

1

1 reference

1 August 2017

Min Kyu Park

2

1 reference

1 August 2017

Tae-Eun Kim

3

1 reference

1 August 2017

Mi Young Bahng

4

1 reference

1 August 2017

Kyoung Soo Lim

5

1 reference

1 August 2017

Sang-Heon Cho

6

1 reference

1 August 2017

Seo Hyun Yoon

7

1 reference

1 August 2017

In-Jin Jang

9

1 reference

1 August 2017

Kyung-Sang Yu

10

1 reference

1 August 2017

language of work or name

0 references

publication date

6 October 2014

1 reference

1 August 2017

Drug Design, Development and Therapy

1 reference

1 August 2017

8

1 reference

1 August 2017

1709-1721

1 reference

1 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Standards of medical care in diabetes--2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Diurnal pattern to insulin secretion and insulin action in healthy individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Pharmacokinetic study of saxagliptin in healthy Chinese subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

A review of gliptins in 2011.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Incretin effect: GLP-1, GIP, DPP4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

DPP-4 inhibitors: what may be the clinical differentiators?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

The incretin system and its role in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

Diurnal variation in blood sugar and serum insulin in response to glucose and/or glucagon in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

6 July 2018

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

27 October 2018

A diabetes report card for the United States: quality of care in the 1990s

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199987

27 October 2018

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25336915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm

1 reference

https://pubmed.ncbi.nlm.nih.gov/25336915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[GLP-1 (7-36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25336915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25336915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25336915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/DDDT.S65678

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34353892&oldid=2143974112"